Non-G12C mutant inhibitors Non-G12C KRAS mutations, particularly G12D and G12V, are highly prevalent in PDAC and CRC and lack a cysteine residue for covalent targeting, necessitating alternative therapeutic strategies.46 MRTX1133 was the first non-covalent KRAS-G12D inhibitor (G12Di) discovered through structure-based design, binding both GDP-bound and GTP-bound states with ~700-fold selectivity over wild-type KRAS protein.47 In PDAC mouse models, it induced tumour regression and shifted tumours towards a classical phenotype, enhancing chemosensitivity.48 Although MRTX1133 advanced to a phase 1/2 trial (NCT05737706), the study was terminated in 2025 due to variable and suboptimal pharmacokinetics despite an acceptable safety profile
Thnh phn: L-Citrulline 2500mg Caffeine 400mg Betaine 1400mg TeaCrine 60mg Evodiamine 7.5mg Yohimbine Hydrochloride 5mg Yohimbe Extract 1.5mg Rauwolfa vomitoria Extract 0.5mg u im ni bt: im c bit ln nht ca 3XT Max Energy chnh l s hu phc hp Yohimbine HCl, Yohimbine Extract (as Pausinystalia Yohimbe) & Rauwolfa Vomitoria Extract (as 90% Alpha Yohimbine)
Mahmoud AM, Hussein OE, Abd El-Twab SM, Hozayen WG (2019) Ferulic acid protects against methotrexate nephrotoxicity via activation of Nrf2/ARE/HO-1 signaling and PPAR, and suppression of NF-B/NLRP3 inflammasome axis
V thit k bao b ca kem chng nng MoonLook Kem chng nng MoonLook Glutathione UV Sun Cream c thit k vi bao b dng tup nha nh gn, thun tin mang theo bn ngi
c bit, sn phm cung cp m siu n nh, khin cho da ca mnh lun cm thy cng mn v mm mi, ngay c sau khi thc dy vo mi bui sng
Chronologic trends of cancer-related lymph node research in PubMed: informetrics analysis
